Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Strong pneumonia vaccine sales help Pfizer to top Street estimates

Excluding one-off items, Pfizer earned US$0.67 a share, beating the average analyst estimate of US$0.64 per share
lungs
Prevnar accounted for 11.5% of Pfizer’s total quarterly revenue

Strong sales of its blockbuster pneumonia vaccine Prevnar helped Pfizer Inc (NYSE:PFE) to top market forecasts with its third quarter results.

The largest drugmaker in the US sold just over US$1.5bn worth of Prevnar in the quarter, down nearly 1% from a year earlier but ahead of Wall Street expectations of US$1.46bn.

Revenues rise for first time in four qaurters

The vaccine helped net income to more than double to US$2.84bn, or US$0.47 a share. Excluding one-off items, Pfizer earned US$0.67 a share, beating the average analyst estimate of US$0.64 per share.

Total revenues rose 1% to US$13.17bn, in line with market forecasts. The small uptick did mark the first time in four quarters that the top line registered growth.

After the strong quarterly performance, Pfizer upped the midpoint of its full-year adjusted earnings forecast by US$0.03 to a range of US$2.58 to US$2.62.

The New York-based group also tightened its revenue guidance to US$52.4bn to US$53.1bn, from US$52bn to US$54bn.

‘Wave of product launches ahead’

“Looking ahead, we are encouraged by the convergence of two positive trends: an expected decline in the unfavourable revenue impact associated with product losses of exclusivity and the beginning of an expected multiyear wave of potential new product launches and product line extensions driven by our pipeline,” said chief executive Ian Read.

“We believe that the convergence of these trends, coupled with anticipated continued strong growth from the aforementioned innovative products, positions the Company for long-term success.”

Pfizer added that it would make a decision on whether or not to sell or keep part or all of its consumer health business in 2018.

Shares dipped 0.7% to US$34.91 in early deals on Tuesday.

View full PFE profile View Profile

Pfizer Timeline

Article
November 23 2015

Related Articles

test tubes in a laboratory
November 06 2017
“We are delighted that RedX has exited administration as a going concern and with a strengthened board and management team that will ensure enhanced oversight and provide relevant industry expertise as well as continuity to the business”
mri scanner
January 31 2018
It is actively supporting the hunt for breakthrough treatments for Alzheimer’s, Parkinson’s, Huntingdon’s and multiple sclerosis
m&a icon of bug fish swallowing big fish
December 04 2017
It is paying an initial US$13mln for Vamousse, which it is acquiring from TyraTech, the AIM-listed developer of the range. This will be followed by a deferred pay-out of as much as US$4.5mln based on sales targets

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use